Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma completed enrollment in its Phase 2 Seabreeze STAT studies for rademikibart in asthma and COPD, with topline data expected in September 2026. The company reported $31.5 million in cash and equivalents, providing a runway of at least one year to fund operations through the upcoming data readout.
Key figures
- Revenue
- 2937000
- Guidance
- Cash runway expected for at least one year from the date of this release
- Net loss
- 36682000
- Rd expense
- 31303000
- Cash balance
- 31486000
- Remaining milestones potential
- $99 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.